Researcher basic information

• 博士（臨床薬学）, 北海道大学, Mar. 2021

• https://researchmap.jp/ksk0602?lang=en

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201901004535173428
• https://www.researchgate.net/profile/Keisuke_Okamoto

• 201901004535173428

• リバーストランスレーショナル研究
• ドラッグリポジショニング
• 臨床薬剤学
• 医薬品適正使用

• Bachelor's degree program, School of Pharmaceutical Sciences and Pharmacy
• Master's degree program, Graduate School of Life Science
• Doctoral (PhD) degree program, Graduate School of Life Science

Research activity information

• Jul. 2026, 第18回日本がん薬剤学会（JSOPP）学術大会, 最優秀演題賞
  岡本敬介
• Jul. 2026, 第9回フレッシャーズ・カンファランス, 優秀演題発表賞
  青栁 亮一;古堅 彩子;鳴海 克哉;岡本 敬介;上田 一奈太;小林 正紀
• May 2026, 日本薬学会北海道支部第153回例会, 学生優秀発表賞
  植田 彩文;古堅 彩子;西村 あや子;馬詰 武;青栁 亮一;岡本 敬介;鳴海 克哉;上田 一奈太;小林 正紀
• Mar. 2026, 日本薬学会第146年会, 学生優秀発表賞
  青栁 亮一;古堅 彩子;西村 あや子;馬詰 武;石川 修平;鳴海 克哉;岡本 敬介;上田 一奈太;小林 正紀
• Feb. 2026, 令和7年度旭川薬剤師会･旭川病院薬剤師会合同フォーラム, 優秀演題賞
  菊谷 由里香;寺田 和文;森 綾子;鳴海 克哉;上田 一奈太;岡本 敬介;廣川 力教;小林 正紀
• Nov. 2025, 第35回日本医療薬学会年会, 優秀演題賞
  岡本敬介
• Nov. 2025, 第19回日本薬局学会学術総会, 優秀演題賞（ポスター）
  岡本敬介
• Jul. 2025, 日本薬学会, 2026年度長井記念若手薬学研究者賞
  岡本 敬介
• Jun. 2025, 第8回フレッシャーズ・カンファランス, 優秀演題発表賞
  向井悠斗;山口敦史;菅沼雄大;岡本敬介;松本憲之;上田一奈太;鳴海克哉;小林正紀
• May 2025, 日本薬学会北海道支部第152回例会, 学生優秀発表賞（ポスター発表部門）
  松本憲之;向井悠斗;菅沼雄大;村松ゆかり;山口敦史;上田一奈太;岡本敬介;鳴海克哉;山田勇磨;小林正紀
• Oct. 2024, 第18回次世代を担う若手のための医療薬科学シンポジウム, 優秀発表賞（ポスター発表）
  上田 一奈太;鳴海 克哉;岡本 敬介;古堅 彩子;小林 正紀
• Aug. 2024, 第37回北海道薬物作用談話会, 若手研究者優秀発表賞
  坂田浩太郎;岡本敬介;齋藤佳敬;古堅彩子;鳴海克哉;小林正紀
• Jul. 2024, 第40回日本TDM学会・学術大会, 学生優秀演題賞
  石川陽菜;古堅彩子;西村あや子;馬詰武;青栁亮一;石川修平;鳴海克哉;岡本敬介;武隈洋;菅原満;小林正紀
• Jul. 2024, 日本薬学会北海道支部第151回例会, 学生優秀発表賞
  澤田理子, 古堅彩子, 植田彩文, 西村あや子, 馬詰武, 鳴海克哉, 岡本敬介, 小林正紀
• Jul. 2024, 日本薬学会北海道支部, 2024年度日本薬学会北海道支部奨励賞
  岡本敬介
• 2022, 日本医療薬学会, Postdoctoral Award
  岡本敬介
• Mar. 2021, 日本薬学会 第141年会, 学生優秀発表賞
  岡本敬介
• Jun. 2017, 日本医療薬学会 第1回 フレッシャーズ・カンファランス, 優秀演題賞
  岡本敬介

• Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line
  Keisuke Okamoto; Toya Matsui; Yurika Kikutani; Hinata Ueda; Ayako Furugen; Katsuya Narumi; Masaki Kobayashi
  Biological and Pharmaceutical Bulletin, 49, 9, 1438, 1443, Pharmaceutical Society of Japan, Sep. 2026, [Peer-reviewed], [Lead author]
  Scientific journal
• Everolimus Breast Milk Transfer After Liver Transplantation
  Nozomi Yoshimoto; Hinata Ueda; Masaki Kobayashi; Katsuya Narumi; Keisuke Okamoto; Satoshi Matsuzawa; Kayo Tomimori; Michika Yamaguchi; Naoki Yoshikawa; Ryuji Ikeda; Shinji Katsuragi
  Breastfeeding Medicine, SAGE Publications, Aug. 2026, [Peer-reviewed]
  Scientific journal, Background:
  
  Improving survival after liver transplantation has increased pregnancy rates among women of reproductive age, raising critical questions about breastfeeding safety with maintenance immunosuppressants. Quantitative human data on everolimus transfer into breast milk remain extremely limited.
  
  Methods:
  
  Pharmacokinetic assessment of everolimus (0.25 mg/day once daily) was performed in a woman postpartum day 5 after cesarean delivery. Maternal whole-blood and breast milk samples were collected under steady-state conditions. Whole-blood concentrations were measured by automated immunoassay; breast milk concentrations were quantified by liquid chromatography–tandem mass spectrometry (LC–MS/MS).
  
  Results:
  
  Maternal whole-blood concentrations peaked at 4 hours (1.98 ng/mL). Breast milk concentrations showed a delayed peak at 9 hours (0.117 ng/mL). Using the linear trapezoidal method, the milk-to-whole-blood AUC0-24 ratio was 0.078, and the estimated relative infant dose (RID) was 0.30%.
  
  Conclusion:
  
  This first liver transplant case demonstrates minimal transfer of everolimus into breast milk, with an estimated RID of 0.30% and delayed mammary peak kinetics. High-sensitivity LC-MS/MS enabled reliable quantification even at minimal maternal doses. Although limited to a single case, these findings provide clinically relevant human pharmacokinetic data to support individualized breastfeeding counseling in everolimus-treated liver transplant recipients.
• Automating the roter interaction analysis system for medication counseling: A transformer-based deep learning approach with generative AI-augmented data
  Ayako Mori; Satoshi Watabe; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Hayato Kizaki; Shungo Imai; Keisuke Okamoto; Hinata Ueda; Mitsuru Sugawara; Satoko Hori; Masaki Kobayashi
  Research in Social and Administrative Pharmacy, Elsevier BV, Jun. 2026, [Peer-reviewed]
  Scientific journal
• UPLC–MS/MS Method for Quantifying Non-stimulant ADHD Medications in Human Breast Milk and Plasma: Application in a Lactating Patient Receiving Atomoxetine
  Ryoichi Aoyagi; Ayako Furugen; Ayako Nishimura; Takeshi Umazume; Shuhei Ishikawa; Katsuya Narumi; Keisuke Okamoto; Hinata Ueda; Masaki Kobayashi
  Journal of Pharmaceutical and Biomedical Analysis, 117575, 117575, Elsevier BV, May 2026, [Peer-reviewed]
  Scientific journal
• Ganoderic Acid A Derived from Reishi Mushroom <i>Ganoderma lucidum</i> Protects against Intestinal Immunity Reduction Due to Oxidative Stress in Rat
  Atsuhito Kubota; Keisuke Okamoto; Genki Yasuda; Katsuya Narumi; Yuji Suzuki; Hinata Ueda; Ayako Mori; Natsuko Takahashi-Suzuki; Takashi Satoh; Ken Iseki; Masaki Kobayashi
  Biological and Pharmaceutical Bulletin, 49, 4, 701, 707, Pharmaceutical Society of Japan, Apr. 2026, [Peer-reviewed], [Lead author]
  Scientific journal
• Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel
  Ayami Ueda; Ayako Furugen; Ayako Nishimura; Takeshi Umazume; Ryoichi Aoyagi; Keisuke Okamoto; Katsuya Narumi; Hinata Ueda; Masaki Kobayashi
  Journal of Pharmaceutical Health Care and Sciences, Springer Science and Business Media LLC, Jan. 2026, [Peer-reviewed]
  Scientific journal
• Evaluation of intestinal absorption of deoxyribonucleic acid components in salmon milt extract using in-situ and in vitro gastrointestinal absorption models
  Rin Taguchi; Katsuya Narumi; Hinata Ueda; Hiroshi Satoh; Takao Mori; Keisuke Okamoto; Ayako Furugen; Masaki Kobayashi
  Bioscience, Biotechnology, and Biochemistry, Oxford University Press (OUP), Jan. 2026, [Peer-reviewed]
  Scientific journal, Abstract
  
  Salmon milt extract (SME) is rich in deoxyribonucleic acids and has been suggested as a functional material. However, whether these components contribute to SME’s functionality remains unclear, and data on their intestinal absorption are limited. This study investigated absorption mechanisms of deoxyribonucleic acid components in SME using in-situ and in vitro models. UPLC-MS/MS was used to simultaneously quantify four deoxyribonucleosides (dNs). The in-situ rat intestinal loop study showed increased levels of 2ʹ-deoxyadenosine (dAdo) and 2ʹ-deoxyguanosine (dGuo) in the portal vein. In the transcellular transport assay, dAdo and dGuo levels on the receiver side increased in a time-dependent manner after SME treatment, particularly in human induced pluripotent stem cell-derived small intestinal epithelial cells. No increase in 2ʹ-deoxycytidine or thymidine levels was observed under any experimental condition. These results indicate that purine dNs are absorbed into the portal vein after oral intake of SME, whereas intestinal absorption of pyrimidine dNs is limited.
• Association between the Expression of Monocarboxylate Transporters in Tumors and Surrounding Stromal Cells and Cancer Prognosis: A Meta-Analysis
  Yuto Mukai; Atsushi Yamaguchi; Yudai Suganuma; Keisuke Okamoto; Noriyuki Matsumoto; Katsuya Narumi; Masaki Kobayashi
  Biological and Pharmaceutical Bulletin, 48, 12, 1960, 1971, Pharmaceutical Society of Japan, Dec. 2025, [Peer-reviewed]
  Scientific journal
• Assessment for Resolving Clinical Questions Using Meta-analysis and Basic Studies
  Keisuke Okamoto
  YAKUGAKU ZASSHI, 145, 11, 871, 875, Pharmaceutical Society of Japan, Nov. 2025, [Invited], [Lead author, Corresponding author]
  Japanese, Scientific journal
• Quetiapine Competitively Inhibits Aldehyde Oxidase-Mediated Reduction
  Hinata Ueda; Shuho Asano; Katsuya Narumi; Ryoichi Aoyagi; Keisuke Okamoto; Masaki Kobayashi
  Drug Metabolism and Disposition, 100169, 100169, Elsevier BV, Sep. 2025, [Peer-reviewed]
  Scientific journal
• Effect of Acid Suppressants on Adverse Events of Immune Checkpoint Inhibitors Using Real-world Databases
  KEISUKE OKAMOTO; JURI TAKIZAWA; HINATA UEDA; KATSUYA NARUMI; MASAKI KOBAYASHI
  Anticancer Research, 45, 8, 3287, 3293, International Institute of Anticancer Research, Aug. 2025, [Peer-reviewed], [Lead author, Corresponding author]
  Scientific journal
• Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study
  Keisuke Okamoto; Yoshitaka Saito; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Katsuya Narumi; Mitsuru Sugawara; Masaki Kobayashi
  International Journal of Clinical Oncology, Springer Science and Business Media LLC, Jul. 2025, [Peer-reviewed], [Lead author]
  Scientific journal
• Evaluation of the Effect of Aldehyde Oxidase Inhibitors on 6-Mercaptopurine Metabolism
  Hinata Ueda; Katsuya Narumi; Ayako Furugen; Keisuke Okamoto; Yoshitaka Saito; Masaki Kobayashi
  Biological and Pharmaceutical Bulletin, 48, 5, 713, 720, Pharmaceutical Society of Japan, May 2025, [Peer-reviewed]
  Scientific journal
• Validity and Utility of a Risk Prediction Model for Wound Infection After Lower Third Molar Surgery
  Akira Yamagami; Katsuya Narumi; Yoshitaka Saito; Ayako Furugen; Shungo Imai; Keisuke Okamoto; Yoshimasa Kitagawa; Yoichi Ohiro; Ryo Takagi; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Oral Diseases, Wiley, Jan. 2025
  Scientific journal, ABSTRACT
  
  Objectives
  
  To externally validate a clinical prediction model for surgical site infection (SSI) after lower third molar (L3M) surgery and evaluate its clinical usefulness.
  
  Methods
  
  We conducted a retrospective cohort study of patients who underwent L3M surgery at Hokkaido University Hospital. The study was designed to evaluate the historical and methodological transportability. Clinical usefulness was evaluated using decision curve analysis on the data of the non‐antibiotic‐treated patients.
  
  Results
  
  We obtained 2543 validation cohorts from April 2020 to March 2023, and 640 non‐antibiotic cohorts from July 2010 to September 2023. The incidences of SSI after L3M surgery were 5.3% (135/2543) and 7.7% (49/640) in the validation and non‐antibiotic cohorts, respectively. The discrimination ability of the prediction model was acceptable for the external validation cohort (c‐statistic: 0.67; 95% CI: 0.62–0.71) and adequate for the non‐antibiotic cohort (c‐statistic: 0.72; 95% CI: 0.63–0.79). In both cohorts, the model showed excellent calibration between the observed and predicted probabilities. Decision curve analysis showed increased net benefit across a range of meaningful risk thresholds.
  
  Conclusion
  
  A simple risk prediction model for SSI after L3M surgery demonstrated clinical transportability and usefulness. This model may help surgeons/clinicians determine the appropriateness of prophylactic antibiotics administration for patients in L3M surgery.
• Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples
  Hina Ishikawa; Ayako Furugen; Ayako Nishimura; Takeshi Umazume; Shuhei Ishikawa; Ryoichi Aoyagi; Katsuya Narumi; Keisuke Okamoto; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Journal of Pharmaceutical and Biomedical Analysis, 251, 116432, 116432, Elsevier BV, Dec. 2024, [Peer-reviewed]
  Scientific journal
• Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy
  ATSUSHI YAMAGUCHI; YOSHITAKA SAITO; KEISUKE OKAMOTO; AYAKO FURUGEN; KATSUYA NARUMI; YOH TAKEKUMA; JUN SAKAKIBARA-KONISHI; YASUSHI SHIMIZU; ICHIRO KINOSHITA; MITSURU SUGAWARA; MASAKI KOBAYASHI
  In Vivo, 38, 6, 2886, 2896, Anticancer Research USA Inc., Oct. 2024, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND/AIM: Immune-related adverse events (irAEs) occur in various organs, and sometimes multiply following treatment with immune checkpoint inhibitors (ICIs). This study aimed to determine the association between the number of irAEs and clinical outcomes. PATIENTS AND METHODS: This was a retrospective study that included patients with lung cancer, melanoma, and head and neck cancer who were treated with anti-programmed cell death (ligand) 1 (PD-1/PD-L1) monotherapy. We evaluated the association between the number of irAEs and progression-free survival (PFS) in the simple Cox regression analysis. To eliminate the immortal-time bias, an additional landmark analysis was performed. RESULTS: In total, 92, 69, and 37 patients were allocated to the no, single, and multisystem irAEs groups, respectively. The multisystem irAEs were associated with better PFS compared to the no irAE group. In contrast, at the 12-week landmark, multisystem irAEs were associated with poor PFS compared to the no irAEs group. Furthermore, the rate of treatment suspension owing to irAEs in the multisystem irAEs group (62.5%) was higher than that in the single irAE group (17.3%) at the 12-week landmark. CONCLUSION: The incidence of multisystem irAEs was associated with improved clinical outcomes in patients with lung cancer, melanoma, and head and neck cancer treated with PD-1/PD-L1 inhibitor monotherapy. However, these results may be influenced by a potential immortal-time bias. When accounting for this bias, the early development of multisystem irAEs within 12 weeks was linked to treatment suspension and poorer clinical outcomes.
• Relationship between magnesium dosage and the preventive effect on cisplatin-induced nephrotoxicity: meta-analysis and meta-regression analysis
  Keisuke Okamoto; Yoshitaka Saito; Atsushi Yamaguchi; Katsuya Narumi; Masaki Kobayashi
  International Journal of Clinical Oncology, Springer Science and Business Media LLC, 24 Sep. 2024, [Peer-reviewed], [Lead author]
  Scientific journal
• Salmon Milt Extract Suppresses Glucose Uptake by Downregulating SGLT1 and GLUT2 Expression in Caco-2 Cells
  Taichi Sato; Katsuya Narumi; Rin Taguchi; Komei Ishihara; Hiroshi Satoh; Takao Mori; Keisuke Okamoto; Ayako Furugen; Masaki Kobayashi
  Biological and Pharmaceutical Bulletin, 47, 9, 1477, 1483, Pharmaceutical Society of Japan, 04 Sep. 2024, [Peer-reviewed]
  Scientific journal
• Monocarboxylate Transporters 1 and 2 Are Responsible for L-Lactate Uptake in Differentiated Human Neuroblastoma SH-SY5Y Cells
  Tomoya Sakuma; Yuto Mukai; Atsushi Yamaguchi; Yudai Suganuma; Keisuke Okamoto; Ayako Furugen; Katsuya Narumi; Shuhei Ishikawa; Yoshitaka Saito; Masaki Kobayashi
  Biological and Pharmaceutical Bulletin, 47, 4, 764, 770, Pharmaceutical Society of Japan, 04 Apr. 2024, [Peer-reviewed]
  Scientific journal
• Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis
  YOSHITAKA SAITO; TATSUHIKO SAKAMOTO; MASAKI KOBAYASHI; YOH TAKEKUMA; ISSEI HIGUCHI; KEISUKE OKAMOTO; JUN SAKAKIBARA-KONISHI; YASUSHI SHIMIZU; ICHIRO KINOSHITA; MITSURU SUGAWARA
  In Vivo, 38, 2, 800, 806, Anticancer Research USA Inc., 28 Feb. 2024, [Peer-reviewed]
  Scientific journal
• Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis
  Keisuke Okamoto; Yoshitaka Saito; Atsushi Yamaguchi; Yoh Takekuma; Mitsuru Sugawara
  International Journal of Clinical Oncology, Springer Science and Business Media LLC, 08 Jul. 2023, [Peer-reviewed], [Lead author]
  Scientific journal
• Association between α-defensin 5 and the expression and function of P-glycoprotein in differentiated intestinal Caco-2 cells.
  Genki Yasuda; Atsuhito Kubota; Keisuke Okamoto; Katsuya Narumi; Ayako Furugen; Izumi Kato; Ayako Mori; Yoshitaka Saito; Takashi Satoh; Natsuko Takahashi-Suzuki; Ken Iseki; Masaki Kobayashi
  Biopharmaceutics & drug disposition, 05 Jun. 2023, [Peer-reviewed], [International Magazine]
  English, Scientific journal, α-Defensin 5 is known to be secreted by Paneth cells in the small intestine and plays an important role in eliminating pathogenic microorganisms. It has been reported that a decrease in α-defensin 5 level in the human small intestine is a risk of inflammatory bowel disease (IBD). Furthermore, P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter superfamily, encoded by the ABCB1/MDR1 gene, plays an important role in the front line of host defense by protecting the gastrointestinal barrier from xenobiotic accumulation and may contribute to the development and persistence of IBD. Therefore, we examined the relationship between α-defensin 5 and the expression and function of P-gp using a human gastrointestinal model cell line (Caco-2). We found that MDR1 mRNA and P-gp protein level were increased in Caco-2 cells as well as α-defensin 5 secretion corresponded with the duration of cell culture. Exposure to α-defensin 5 peptide and recombinant tumor necrosis factor-α (TNF-α) significantly increased the expression and function P-gp. The mRNA levels of interleukin (IL)-8, IL-6, TNF-α, IL-1β, and IL-2 were also increased following exposure to TNF-α, similar to α-defensin 5 treatment. These results suggest that α-defensin 5 regulates P-gp expression and function by increasing TNF-α expression in Caco-2 cells.
• Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis
  Yoshitaka Saito; Tatsuhiko Sakamoto; Yoh Takekuma; Masaki Kobayashi; Keisuke Okamoto; Naofumi Shinagawa; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific Reports, 12, 1, 21819, 21819, Springer Science and Business Media LLC, Dec. 2022, [Peer-reviewed], [International Magazine]
  English, Scientific journal, Abstract
  
  Cisplatin (CDDP)-induced nephrotoxicity (CIN) is dose-limiting. We revealed that co-administration of non-steroid anti-inflammatory drugs and baseline comorbidity of diabetes mellitus (DM) are associated with CIN development in the short hydration method; however, the results were accessorily obtained without appropriate power calculation. This study aimed to demonstrate the influence of DM complications on CIN incidence in a real-world setting. Lung cancer patients receiving CDDP (≥ 75 mg/m²)-containing regimens with a short hydration method (n = 227) were retrospectively evaluated. The patients were divided into control and baseline DM complication groups. The primary endpoint was the evaluation of CIN incidence between the groups. Propensity score-matching was performed to confirm the robustness of the primary analysis results. CIN occurred in 6.8% of control and 27.0% of DM patients, respectively, with a significant difference in all-patient populations (P = 0.001). In addition, variation of serum creatinine and creatinine clearance significantly worsened in DM patients. Similar results were obtained in a propensity-matched population. Multivariate logistic regression analysis found that DM complication is a singular risk factor for CIN development (adjusted odds ratio; 4.31, 95% confidence interval; 1.62–11.50, P = 0.003). In conclusion, our study revealed that baseline DM complications significantly worsen CIN.
• Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity
  Keisuke Okamoto; Hinata Ueda; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Masaki Kobayashi
  Drug Metabolism and Pharmacokinetics, 41, 100417, 100417, Elsevier BV, Aug. 2021, [Peer-reviewed], [Lead author]
  Scientific journal
• Anticancer effects of non-steroidal anti-inflammatory drugs against cancer cells and cancer stem cells
  Keisuke Okamoto; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Ken Iseki; Masaki Kobayashi
  Toxicology in Vitro, 74, 105155, 105155, Elsevier BV, Aug. 2021, [Peer-reviewed], [Lead author]
  Scientific journal
• Antioxidant effect of ascorbic acid against cisplatin-induced nephrotoxicity and P-glycoprotein expression in rats
  Keisuke Okamoto; Fumi Kitaichi; Yoshitaka Saito; Hinata Ueda; Katsuya Narumi; Ayako Furugen; Masaki Kobayashi
  European Journal of Pharmacology, 909, 174395, 174395, Elsevier BV, Jul. 2021, [Peer-reviewed], [Lead author]
  Scientific journal
• Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells
  Keisuke Okamoto; Yoshitaka Saito; Hinata Ueda; Katsuya Narumi; Ayako Furugen; Masaki Kobayashi
  Biopharmaceutics & Drug Disposition, 42, 8, 389, 392, Wiley, Jul. 2021, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, Cystine/glutamate transporter (xCT) is an antiporter involved in cystine uptake and glutamate efflux. However, there are very few reports regarding the kinetic analysis of xCT for cystine uptake using cancer cell lines, as well as the inhibition pattern of sulfasalazine, an inhibitor of xCT, for cystine uptake. Therefore, the purpose of this study was to clarify the kinetics of xCT in A549 cells, human lung cancer cells, and to reveal the inhibition pattern of sulfasalazine. Cystine uptake occurred in a time-dependent manner, with linear cystine uptake observed for 5 min. Additionally, sulfasalazine inhibited cystine uptake in a concentration-dependent manner, presenting an IC50 value of 24.7 ± 5.6 μM. Cystine uptake was saturated with increasing concentration, demonstrating Km and Vmax values of 179.4 ± 26.7 μM and 30.4 ± 2.3 nmol/min/mg protein, respectively. Moreover, during cystine uptake with sulfasalazine, Km and Vmax were >300 μM and 8.0 ± 1.5 nmol/min/mg protein, respectively, suggesting that sulfasalazine might demonstrate a mixed inhibition pattern. Furthermore, xCT siRNA decreased the xCT mRNA level and reduced cystine uptake. In conclusion, xCT was involved in the cystine uptake in A549 cells and sulfasalazine showed a mixed inhibition pattern to xCT.
• Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis
  Atsushi Yamaguchi; Yoshitaka Saito; Keisuke Okamoto; Katsuya Narumi; Ayako Furugen; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Supportive Care in Cancer, Springer Science and Business Media LLC, Jun. 2021, [Peer-reviewed], [International Magazine]
  English, Scientific journal, PURPOSE: Patients with preexisting autoimmune disease (PAD) are often excluded from clinical trials assessing immune checkpoint inhibitors (ICIs). Therefore, the safety of ICI therapy in patients with PAD remains unclear. Herein, we evaluated the incidence of immune-related adverse events (irAEs) in patients with PAD when compared with non-PAD patients. METHODS: We searched MEDLINE/PubMed, Web of Science, and Google Scholar for eligible studies from inception to January 2021. Observational studies reporting the incidence of irAEs in patients with and without PAD were included. We then performed a meta-analysis of eligible studies using forest plots. The primary endpoint of this study was the incidence rate of irAEs between patients with and without PAD. RESULTS: We identified three prospective and three retrospective studies involving 206 patients with PAD and 3078 patients without PAD. In the meta-analysis, 128 patients with PAD (62.1%) experienced irAEs, which occurred in 51.9% of non-PAD patients, resulting in an odds ratio (OR) of 2.14 (95% confidence interval [CI] 1.58-2.89). In the subgroup analysis, the incidence of irAEs was significantly higher in patients with PAD (OR = 2.19, 95% CI [1.55-3.08]). Furthermore, no significant heterogeneity or publication bias was detected, indicating that our meta-analysis could be generalized to clinical settings. CONCLUSION: This meta-analysis demonstrated that PAD was a risk factor for irAE incidence. These results suggest that monitoring the occurrence of irAEs in patients with PAD is required to manage irAEs appropriately.
• Different mechanisms of cisplatin resistance development in human lung cancer cells.
  Keisuke Okamoto; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Ken Iseki; Masaki Kobayashi
  Biochemical and biophysical research communications, 530, 4, 745, 750, Elsevier BV, 08 Aug. 2020, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, Cisplatin (CDDP) is a highly potent and important anticancer drug in lung cancer treatment. Long-term use of an anticancer agent causes resistance in cancer cells, and CDDP resistance involves multiple mechanisms. As the mechanism of resistance development differs depending on the cancer cell types, we aimed to evaluate the detailed mechanism of resistance to CDDP in two types of lung cancer cells: SBC-3 and A549 cells. The CDDP-resistant SBC-3/DDP and A549/DDP cells were established through continuous treatment with a gradually increasing dose of CDDP. The viability of SBC-3/DDP and A549/DDP cells treated with CDDP was 3.68 and 2.08 times higher than that of the respective parental cells. Moreover, SBC-3/DDP cells showed significantly increased cystine/glutamate transporter (xCT) mRNA level, and A549/DDP cells showed markedly increased sex determining region Y-box 2 (SOX2) mRNA level. Moreover, the uptake of cystine, a substrate of xCT, was higher in SBC-3/DDP cells than in SBC-3 cells, and cystine uptake in A549/DDP cells was not different from that in A549 cells. In addition, co-treatment with CDDP and sulfasalazine, an xCT inhibitor, showed lower the concentration of 50% inhibition for cell viability than CDDP alone in SBC-3 and SBC-3/DDP cells, but not in A549 and A549/DDP cells. Furthermore, SBC-3 cells transiently overexpressing xCT were resistant to CDDP, and xCT knockdown in A549/DDP cells did not significantly change the level of SOX2 mRNA and viability of cells upon CDDP treatment. In conclusion, the two lung cancer cell lines showed different mechanisms of resistance to CDDP.
• Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo.
  Keisuke Okamoto; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Ken Iseki; Masaki Kobayashi
  European journal of pharmacology, 884, 173339, 173339, Elsevier BV, 26 Jul. 2020, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, Cisplatin (CDDP) is an anticancer drug, often used in the treatment of several types of cancers. CDDP-induced nephrotoxicity (CIN) is one of the most severe adverse events associated with the use of CDDP. It has been suggested that the co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) is a risk factor for CIN. However, the specific NSAIDs that affect CIN and the precise mechanisms underlying this interaction remain unclear. Hence, we aimed to evaluate the effect of NSAIDs on CDDP-induced cytotoxicity in vitro and confirmed the results in vivo. Using the epithelioid clone of the normal rat kidney cells (NRK-52E cells), we assessed the effects of 17 NSAIDs on CDDP-induced cytotoxicity all at once using the MTT assay. Furthermore, we evaluated two NSAIDs, which significantly attenuated or enhanced CDDP-induced cytotoxicity, in vivo. Wistar rats were treated with CDDP (5 mg/kg, i.p., day 1) and NSAIDs (p.o., day 1-4), and the kidneys were excised on day 5. Our results demonstrated that several NSAIDs attenuated, while others enhanced CDDP-induced cytotoxicity. Celecoxib significantly attenuated and flurbiprofen markedly enhanced cell dysfunction by CDDP. These results were reproduced in vivo as celecoxib decreased and flurbiprofen increased the expression of kidney injury molecule 1 (Kim-1) mRNA, a sensitive kidney injury marker, compared to the CDDP group. Moreover, celecoxib increased the antioxidant and autophagy markers quantified by qPCR in vitro and prevented a decrease in body weight induced by CDDP in vivo. In conclusion, we revealed that celecoxib significantly attenuated CIN in vitro and in vivo.
• Non-steroidal Anti-inflammatory Drugs Are a Risk Factor for Cisplatin-induced Nephrotoxicity: A Meta-analysis of Retrospective Studies.
  Keisuke Okamoto; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Ken Iseki; Masaki Kobayashi
  Anticancer research, 40, 3, 1747, 1751, Mar. 2020, [Peer-reviewed], [Lead author], [International Magazine]
  English, Scientific journal, BACKGROUND/AIM: Previous reports have demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) are a risk factor for cisplatin-induced nephrotoxicity (CIN). Here, the results of these previous studies were comprehensively assessed via a meta-analysis. MATERIALS AND METHODS: After a database search to select eligible studies, a meta-analysis was performed using a forest plot, followed by an assessment of the heterogeneity and publication bias and a subgroup analysis. RESULTS: Seven studies were extracted as candidates. All were retrospective studies and evaluated the effect of NSAIDs on CIN as a secondary endpoint. According to the meta-analysis, total odds ratio was 1.88 (95% confidence interval=1.44-2.45). Further, high heterogeneity and publication bias were not observed. A subgroup analysis of the chemotherapy evaluation period revealed that CIN tended to be enhanced in the first course group (evaluation in only 1 course) and was significantly enhanced in the total course group (evaluation in 1 or more courses) by NSAIDs co-administration. CONCLUSION: NSAIDs co-administration could be a risk factor for CIN.
• Reishi mushroom Ganoderma lucidum Modulates IgA production and alpha-defensin expression in the rat small intestine.
  Atsuhito Kubota; Masaki Kobayashi; Sota Sarashina; Reiko Takeno; Keisuke Okamoto; Katsuya Narumi; Ayako Furugen; Yuji Suzuki; Natsuko Takahashi; Ken Iseki
  Journal of ethnopharmacology, 214, 240, 243, 25 Mar. 2018, [Peer-reviewed], [International Magazine]
  English, Scientific journal, ETHNOPHARMACOLOGICAL RELEVANCE: Immunoglobulin A (IgA) secretion and alpha-defensins play a role in the innate immune system to protect against infection. Ganoderma lucidum (W.Curt.: Fr.) P. Karst. (Reishi) is a well-known mushroom in traditional Chinese medicine. This study aimed to determine the effects of Reishi on IgA secretion from Peyer's patch (PP) cells and alpha-defensin-5 (RD-5) and RD-6 expression in the rat small intestine. MATERIALS AND METHODS: The rats received an oral injection of 0.5-5mg/kg of Reishi powder (1mL/kg) by sonde. All animals were euthanized 24h after Reishi administration. We examined RD-5, RD-6, and Toll-like receptor (TLR) 4 mRNA levels in the jejunum, ileum, and in Peyer's patches (PP) through quantitative real-time PCR analysis. IgA secretion from PP was measured through enzyme-linked immunosorbent assay of the supernatant after primary culture. RESULTS: Reishi increased IgA secretion in the presence of lipopolysaccharide (LPS) and increased TLR4 mRNA levels, but had no effect on the viability of PP cells. Moreover, Reishi increased RD-5, RD-6, and TLR4 mRNA levels significantly in the ileum in a concentration-dependent manner. CONCLUSIONS: Reishi can induce IgA secretion and increase the mRNA levels of RD-5 and RD-6 in the rat small intestine, through a TLR4-dependent pathway. The present results indicate that Reishi might reduce the risk of intestinal infection.
• Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration
  Yoshitaka Saito; Keisuke Okamoto; Masaki Kobayashi; Katsuya Narumi; Ayako Furugen; Takehiro Yamada; Ken Iseki
  LIFE SCIENCES, 189, 18, 22, Nov. 2017, [Peer-reviewed]
  English, Scientific journal
• Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters
  Yoshitaka Saito; Keisuke Okamoto; Masaki Kobayashi; Katsuya Narumi; Takehiro Yamada; Ken Iseki
  EUROPEAN JOURNAL OF PHARMACOLOGY, 811, 191, 198, Sep. 2017, [Peer-reviewed]
  English, Scientific journal
• Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation
  Chihiro Kaneko; Jiro Ogura; Shunichi Sasaki; Keisuke Okamoto; Masaki Kobayashi; Kaori Kuwayama; Katsuya Narumi; Ken Iseki
  BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1861, 3, 559, 566, Mar. 2017, [Peer-reviewed]
  English, Scientific journal

• Youtubeから学ぶプレゼンの仕方
  札学薬第61号, Mar. 2026, [Invited]
• 話題の薬
  北海道大学薬学部同窓会誌芳香75号, Mar. 2026, [Invited]
• ナカジマ薬局 プレスリリース
  ナカジマ薬局ホームページ, Nov. 2025
  Others
• 長井記念薬学研究奨励支援事業は研究の推進力
  岡本敬介, ファルマシア, 60, 12, 1138, Dec. 2024, [Invited]
• 免疫チェックポイント阻害薬と胃酸分泌抑制薬との関連と今後の課題
  岡本敬介, Helicobacter Research, 26, 2, 84, 87, Dec. 2022, [Invited]
  Introduction scientific journal

• 酸化ストレス応答転写因子NRF2によるAOX1発現制御機構の解析
  石橋利矩; 鳴海克哉; 石原孔明; 上田一奈太; 岡本敬介; 小林正紀
  第38回北海道薬物作用談話会, Aug. 2026, Oral presentation
• 〔主要な業績〕プロトンポンプ阻害薬がカペシタビン起因性手足症候群へ及ぼす影響の評価
  行徳 千歳; 岡本 敬介; 鳴海 克哉; 上田 一奈太; 小林 正紀
  第38回北海道薬物作用談話会, Aug. 2026, Oral presentation
• 神経由来細胞におけるMCTsを介したラクチル化制御に関する研究
  松本 憲之; 向井 悠斗; 菅沼 雄大; 中野 広大; 石川 修平; 上田 一奈太; 岡本 敬介; 鳴海 克哉; 小林 正紀
  第38回北海道薬物作用談話会, Aug. 2026, Oral presentation
• サケ白子抽出物が腸管上皮防御機構に及ぼす影響
  羽田野友香; 鳴海克哉; 佐藤浩志; 盛孝男; 上田一奈太; 岡本敬介; 小林正紀
  第38回北海道薬物作用談話会, Aug. 2026, Oral presentation
• シクロホスファミド関連心毒性の発現に及ぼす酸化還元酵素阻害薬の影響 ～JADER/FAERS解析～
  石原孔明; 鳴海克哉; 上田一奈太; 岡本敬介; 小林正紀
  第18回日本がん薬剤学会（JSOPP）学術大会, Jul. 2026, Poster presentation
• 〔主要な業績〕シスプラチン起因性腎障害に対するセレコキシブの影響：ロキソプロフェン・ナプロキセンとの後方視比較検証
  岡本敬介; 齋藤佳敬; 高橋健太; 武隈洋; 榊原純; 鳴海克哉; 上田一奈太; 菅原満; 小林正紀
  第18回日本がん薬剤学会（JSOPP）学術大会, Jul. 2026, Poster presentation
• MCF10F乳腺上皮モデルを用いたADHD治療薬atomoxetineの乳汁移行性と寄与因子の検討
  青栁 亮一; 古堅 彩子; 鳴海 克哉; 岡本 敬介; 上田 一奈太; 小林 正紀
  第9回フレッシャーズ・カンファランス, Jul. 2026, Oral presentation
• モノカルボン酸輸送担体（MCTs）のがん予後因子としてのメタ解析及びデータベース・in vitro 解析による機能的検証
  菅沼 雄大; 向井 悠斗; 松本 憲之; 山口 敦史; 上田 一奈太; 岡本 敬介; 鳴海 克哉; 小林 正紀
  医療薬学フォーラム2026, Jun. 2026, Poster presentation
• シクロホスファミド誘発性心毒性における酸化還元酵素の寄与ーFAERS解析および基礎的検討ー
  石原 孔明; 鳴海 克哉; 上田 一奈太; 岡本 敬介; 小林 正紀
  医療薬学フォーラム2026, Jun. 2026, Poster presentation
• CS分析（Customer Satisfaction analysis）を応用した薬剤業務補助者への研修・教育に対する満足度調査
  菊谷 由里香; 寺田 和文; 森 綾子; 鳴海 克哉; 上田 一奈太; 岡本 敬介; 廣川 力教; 小林 正紀
  第73回北海道薬学大会・北海道病院薬剤師会会員研究発表会, May 2026, Oral presentation
• 第三世代抗てんかん薬の胎盤移行性に関する研究
  植田 彩文; 古堅 彩子; 西村 あや子; 馬詰 武; 青栁 亮一; 岡本 敬介; 鳴海 克哉; 上田 一奈太; 小林 正紀
  日本薬学会北海道支部第153回例会, May 2026, Oral presentation
• 〔主要な業績〕胃酸分泌抑制薬が免疫チェックポイント阻害薬による免疫関連有害事象に及ぼす影響の検証
  滝澤 寿莉; 岡本 敬介; 近田 那央; 上田 一奈太; 鳴海 克哉; 小林 正紀
  日本薬学会北海道支部第153回例会, May 2026, Oral presentation
• 〔主要な業績〕長井記念薬学研究奨励支援事業がもたらす薬学研究の推進力
  岡本敬介
  日本薬学会第146年会, Mar. 2026, Nominated symposium
  [Invited]
• ADHD治療薬のヒト乳汁移行性の解明：ヒト乳汁中薬物濃度解析と乳腺モデル細胞による評価
  青栁 亮一; 古堅 彩子; 西村 あや子; 馬詰 武; 石川 修平; 鳴海 克哉; 岡本 敬介; 上田 一奈太; 小林 正紀
  日本薬学会第146年会, Mar. 2026, Oral presentation
• CS分析(Customer Satisfaction analysis)を応用した薬剤業務補助者への研修・教育に対する満足度調査
  菊谷 由里香; 寺田 和文; 森 綾子; 鳴海 克哉; 上田 一奈太; 岡本 敬介; 廣川 力教; 小林 正紀
  令和7年度旭川薬剤師会･旭川病院薬剤師会合同フォーラム, Feb. 2026, Oral presentation
• クエチアピンによるAOX還元反応の阻害を介した薬物相互作用評価―基礎・疫学的アプローチによる検証―
  鳴海 克哉; 上田 一奈太; 淺野 秀峰; 岡本 敬介; 小林 正紀
  第35回日本医療薬学会年会, Nov. 2025, Poster presentation
• 〔主要な業績〕基礎・臨床研究によるセレコキシブがシスプラチン起因性腎障害に及ぼす影響の検証
  岡本 敬介; 齋藤 佳敬; 高橋 健太; 武隈 洋; 榊原 純; 鳴海 克哉; 上田 一奈太; 菅原 満; 小林 正紀
  第35回日本医療薬学会年会, Nov. 2025, Oral presentation
• 〔主要な業績〕胃酸分泌抑制薬がカペシタビンによる手足症候群に及ぼす影響の検証―薬局の電子薬歴データを用いた解析―
  岡本敬介; 鈴木直哉; 谷口亮央; 染谷光洋; 石川修平; 穴田わかな; 上田一奈太; 鳴海克哉; 小林正紀
  第19回日本薬局学会学術総会, Nov. 2025, Poster presentation
• 神経細胞における乳酸輸送にカプサイシンが及ぼす影響の評価
  松本憲之; 向井悠斗; 菅沼雄大; 上田一奈太; 岡本敬介; 鳴海克哉; 小林正紀
  第13回日本未病学会北海道支部会, Aug. 2025, Poster presentation
• HepG2細胞を用いたアルデヒドオキシダーゼ評価系の構築およびエピジェネティック制御に関する考察
  源尾有紗; 鳴海克哉; 浅野秀峰; 石原孔明; 上田一奈太; 岡本敬介; 小林正紀
  第38回北海道薬物作用談話会, Aug. 2025, Oral presentation
• クロザピン誘発性流涎症に対する治療薬に関する研究
  植野千夏; 石川修平; 上田一奈太; 岡本敬介; 鳴海克哉; 小林正紀
  第38回北海道薬物作用談話会, Aug. 2025, Oral presentation
• 大腿骨骨折術後におけるせん妄発症の予測モデルの開発
  酒井 慶二; 石川 修平; 武藤 健太; 太田 くり; 柏木 智則; 早坂 郁; 岡本 敬介; 鳴海 克哉; 堀 大; 嶋田 進一郎; 小林 正紀
  医療薬学フォーラム2025, Jun. 2025, Poster presentation
• 〔主要な業績〕大腸がん治療薬カペシタビンとプロトンポンプ阻害薬の薬物間相互作用の評価
  行徳 千歳; 岡本 敬介; 鳴海 克哉; 上田 一奈太; 小林 正紀
  医療薬学フォーラム2025, Jun. 2025, Poster presentation
• ADHD治療薬のヒト血漿・乳汁中におけるUPLC/MS/MS定量法の構築
  青栁 亮一; 古堅 彩子; 西村 あや子; 馬詰 武; 石川 修平; 鳴海 克哉; 岡本 敬介; 上田 一奈太; 小林 正紀
  医療薬学フォーラム2025, Jun. 2025, Poster presentation
• 薬物代謝・副作用データベース解析を活用したチオプリン代謝におけるaldehyde oxidase機能評価
  上田 一奈太; 鳴海 克哉; 岡本 敬介; 古堅 彩子; 小林 正紀
  医療薬学フォーラム2025, Jun. 2025, Nominated symposium
  [Invited]
• モノカルボン酸輸送担体の発現とがんの予後に関するメタ解析及びin vitroにおける検討
  向井悠斗; 山口敦史; 菅沼雄大; 岡本敬介; 松本憲之; 上田一奈太; 鳴海克哉; 小林正紀
  第8回フレッシャーズ・カンファランス, Jun. 2025, Poster presentation
• モノカルボン酸輸送担体MCTsの阻害が肝がん細胞株の生存及びエネルギー代謝に与える影響
  松本憲之; 向井悠斗; 菅沼雄大; 村松ゆかり; 山口敦史; 上田一奈太; 岡本敬介; 鳴海克哉; 山田勇磨; 小林正紀
  日本薬学会北海道支部第152回例会, May 2025, Poster presentation
• クエチアピンによるAOX介在性薬物相互作用メカニズムの解明
  淺野秀峰; 上田一奈太; 鳴海克哉; 岡本敬介; 小林正紀
  日本薬学会北海道支部第152回例会, May 2025, Oral presentation
• T細胞急性リンパ性白血病細胞の乳酸輸送に寄与する輸送担体の同定
  菅沼雄大; 向井悠斗; 松本憲之; 山口敦史; 上田一奈太; 岡本敬介; 鳴海克哉; 小林正紀
  日本薬学会北海道支部第152回例会, May 2025, Oral presentation
• 肝細胞がんの治療抵抗性の克服に向けたモノカルボン酸輸送担体を標的とする新規治療戦略
  向井 悠斗; 山口 敦史; 菅沼 雄大; 松本 憲之; 岡本 敬介; 古堅 彩子; 鳴海 克哉; 小林 正紀
  日本薬学会第145年会, Mar. 2025, Poster presentation
• 多発性免疫関連有害事象と免疫チェックポイント阻害薬の治療効果との関連性の解析
  山口敦史; 齋藤佳敬; 岡本敬介; 古堅彩子; 鳴海克哉; 武隈洋; 榊原純; 清水康; 木下一郎; 菅原満; 小林正紀
  第34回日本医療薬学会年会, Nov. 2024, Oral presentation
• 〔主要な業績〕シスプラチン起因性腎障害の予防における硫酸マグネシウム投与量の検証
  岡本敬介; 齋藤佳敬; 山口敦史; 坂田浩太郎; 鳴海克哉; 小林正紀
  第34回日本医療薬学会年会, Nov. 2024, Oral presentation
• アルデヒドオキシダーゼの薬物動態学的重要性および個体間差の解明
  上田 一奈太; 鳴海 克哉; 岡本 敬介; 古堅 彩子; 小林 正紀
  第18回次世代を担う若手のための医療薬科学シンポジウム, Oct. 2024, Poster presentation
• 消化管吸収モデルを用いたサケ白子抽出物由来デオキシリボヌクレオチドの小腸吸収動態評価
  田口凜; 鳴海克哉; 佐藤浩志; 盛孝男; 岡本敬介; 古堅彩子; 小林正紀
  第12回日本未病学会北海道支部会, Sep. 2024, Poster presentation
• 〔主要な業績〕糖尿病治療薬がシスプラチン起因性腎障害に及ぼす影響の評価
  坂田浩太郎; 岡本敬介; 齋藤佳敬; 古堅彩子; 鳴海克哉; 小林正紀
  第37回北海道薬物作用談話会, Aug. 2024, Oral presentation
• AOX1遺伝子の5’上流および3’非翻訳領域におけるSNP解析
  林愛; 鳴海克哉; 上田一奈太; 岡本敬介; 古堅彩子; 小林正紀
  第40回日本TDM学会・学術大会, Jul. 2024, Oral presentation
• オレキシン受容体拮抗薬のUPLC/MS/MS定量法構築とヒト乳汁移行性評価への応用
  石川陽菜; 古堅彩子; 西村あや子; 馬詰武; 青栁亮一; 石川修平; 鳴海克哉; 岡本敬介; 武隈洋; 菅原満; 小林正紀
  第40回日本TDM学会・学術大会, Jul. 2024, Oral presentation
• 下顎埋伏智歯抜歯手術後における手術部位感染予測モデルの外部検証ならびに臨床的有用性評価
  山神彰; 鳴海克哉; 齋藤佳敬; 古堅彩子; 今井俊吾; 岡本敬介; 北川善政; 大廣洋一; 高木諒; 武隈洋; 菅原満; 小林正紀
  日本薬学会北海道支部第151回例会, Jul. 2024, Oral presentation
• サケ白子抽出物に含まれるデオキシリボヌクレオチドの小腸吸収動態評価
  田口凜; 鳴海克哉; 佐藤浩志; 盛孝男; 岡本敬介; 古堅彩子; 小林正紀
  日本薬学会北海道支部第151回例会, Jul. 2024, Oral presentation
• ヒト胎盤幹細胞におけるトランスポーター発現・機能評価
  澤田理子; 古堅彩子; 植田彩文; 西村あや子; 馬詰武; 鳴海克哉; 岡本敬介; 小林正紀
  日本薬学会北海道支部第151回例会, Jul. 2024, Oral presentation
• 〔主要な業績〕マグネシウムの投与量とシスプラチン起因性腎障害予防効果との関連：メタ回帰分析での検証
  岡本敬介; 齋藤佳敬; 山口敦史; 鳴海克哉; 小林正紀
  日本薬剤学会第39年会, May 2024, Poster presentation
• 記憶形成に関与するhMCT2の機能解明と選択性の高い阻害剤の探索
  山口敦史; 向井悠斗; 佐久間智也; 岡本敬介; 古堅彩子; 鳴海克哉; 小林正紀
  日本薬学会第144年会, 30 Mar. 2024, Oral presentation
• 〔主要な業績〕がん免疫療法に及ぼす胃酸分泌抑制薬の影響: メタアナリシスの手法を用いた検証
  岡本敬介; 齋藤佳敬; 武隈洋; 小林正紀; 菅原満
  北海道医療大学 次世代のがんプロフェッショナル養成プラン 第13回がん薬物療法研究討論会, 17 Feb. 2024, Invited oral presentation
  [Invited]
• 〔主要な業績〕胃酸分泌抑制薬が免疫チェックポイント阻害薬の治療効果と副作用へ及ぼす影響の検証
  岡本 敬介; 齋藤 佳敬; 武隈 洋; 菅原 満
  第33回日本医療薬学会年会, Nov. 2023, Oral presentation
• 〔主要な業績〕糖尿病はシスプラチン起因性腎毒性を増悪する
  坂本 達彦; 齋藤 佳敬; 武隈 洋; 小林 正紀; 岡本 敬介; 品川 尚文; 清水 康; 木下 一郎; 菅原 満
  第33回日本医療薬学会年会, Nov. 2023, Oral presentation
• 〔主要な業績〕メタアナリシスによる非ステロイド性抗炎症薬がシスプラチン起因性腎障害に及ぼす影響の検証
  岡本敬介; 齋藤佳敬; 鳴海克哉; 古堅彩子; 武隈洋; 小林正紀; 菅原満
  第26回札幌病院薬剤師会会員発表会, 16 Oct. 2021, Oral presentation
• 〔主要な業績〕シスプラチン起因性腎障害の 適切な軽減方法の探索
  岡本敬介; 齋藤佳敬; 上田一奈太; 北市楓美; 鳴海克哉; 古堅彩子; 井関健; 小林正紀
  第15回次世代を担う若手医療薬科学シンポジウム, Oct. 2021, Poster presentation
• 〔主要な業績〕シスプラチンの副作用と耐性化に着目したNSAIDsの効果の検証
  岡本敬介; 齋藤佳敬; 上田一奈太; 古堅彩子; 鳴海克哉; 小林正紀
  日本薬学会第141年会, Mar. 2021, Oral presentation
• 〔主要な業績〕シスプラチン起因性腎障害モデルにおけるトランスポーター発現変動とその機序に関する研究
  北市楓美; 岡本敬介; 齋藤佳敬; 鳴海克哉; 古堅彩子; 井関健; 小林正紀
  日本薬学会北海道支部第147回例会, May 2020, Oral presentation
• 〔主要な業績〕シスプラチンの抗腫瘍効果を増強させるNSAIDsの探索とシスプラチン起因性腎障害との関連
  岡本敬介; 小林正紀; 齋藤佳敬; 古堅彩子; 鳴海克哉; 井関健
  日本薬学会第140年会, Mar. 2020, Oral presentation
• 〔主要な業績〕リバース・トランスレーショナルリサーチに基づいたシスプラチン起因性腎障害に及ぼすNSAIDsの影響の解析
  岡本敬介; 齋藤佳敬; 小林正紀; 古堅彩子; 鳴海克哉; 井関健
  第29回日本医療薬学会年会, Nov. 2019, Oral presentation
• 〔主要な業績〕マグネシウム投与によるシスプラチン起因性腎障害の予防効果およびその機序の解明
  齋藤佳敬; 小林正紀; 岡本敬介; 秋田弘俊; 井関健
  日本薬学会第139年会, Mar. 2019, Public symposium
• 〔主要な業績〕後方視的臨床研究及びin vivoにおけるマグネシウムのシスプラチン起因性腎障害軽減効果の検証
  岡本敬介; 齋藤佳敬; 小林正紀; 井関健
  第12回次世代を担う若手医療薬科学シンポジウム, Sep. 2018, Poster presentation
• 〔主要な業績〕NSAIDsのCOX選択性がシスプラチン起因性細胞傷害に及ぼす影響
  岡本敬介; 齋藤 佳敬; 古堅 彩子; 鳴海 克哉; 小林 正紀; 井関 健
  日本薬学会第138年会, Mar. 2018, Oral presentation
• 〔主要な業績〕シスプラチン起因性腎障害に対するマグネシウムの軽減効果の機序
  岡本敬介; 齋藤佳敬; 小林正紀; 清水康; 秋田弘俊; 井関健
  日本医療薬学会第1 回フレッシャーズ・カンファランス, Jun. 2017, Oral presentation
• 〔主要な業績〕マグネシウムによるシスプラチン起因性腎障害の軽減効果の機序に関する研究
  岡本敬介; 齋藤佳敬; 小林正紀; 清水 康; 秋田弘俊; 井関 健
  日本薬学会北海道支部第143回例会, May 2016, Oral presentation

• 医療情報解析演習, 2024年, 学士課程, 薬学部
• 実務実習事前実習, 2024年, 学士課程, 薬学部
• OSCE対応演習, 2024年, 学士課程, 薬学部

• 日本薬剤疫学会
• 日本薬局学会
• 札幌学校薬剤師会
• 日本薬剤師会
• 日本薬剤学会
• 日本病院薬剤師会
• JAPANESE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES
• THE PHARMACEUTICAL SOCIETY OF JAPAN

• がん免疫療法における非胃型プロトンポンプを介した胃酸分泌抑制薬の相互作用の検証
  科学研究費助成事業
  Apr. 2025 - Mar. 2027
  日本学術振興会, 若手研究, Principal investigator, 25K18669
• コキシブ系抗炎症薬は抗がん薬の治療効果を低下させるか
  研究助成（グループB）
  Mar. 2025 - Mar. 2027
  公益財団法人薬学研究奨励財団, Principal investigator
• 抗がん剤の副作用と耐性化に着目したcyclooxygenase阻害薬の効果の検証
  科学研究費助成事業
  Apr. 2019 - Mar. 2021
  日本学術振興会, 特別研究員奨励費, Principal investigator, Competitive research funding

• 第72回北海道薬学大会
  May 2025
  Planning etc
• 第40回日本TDM学会・学術大会
  Jul. 2024
  Planning etc
  Academic society etc
• 第22回日本医薬品情報学会総会・学術大会
  Jun. 2019
  Planning etc

• 北海道大学薬学部ＳＰ（模擬患者）会
  Oct. 2023 - Present
  Planner, Organizing member
• 薬物乱用防止教室
  07 Jul. 2026
  Lecturer
  札幌市立川北小学校
• 市民への話題提供「漢方薬に書いてある番号の小話」
  01 Jul. 2026
  Lecturer
  北海道大学薬学部SP会
• 松前町立松前病院 薬剤師派遣業務
  16 Feb. 2026 - 20 Feb. 2026
  Others
• 薬物乱用防止教室
  16 Jul. 2025
  Lecturer
  札幌市立川北小学校
• 薬物乱用防止教室
  23 Jul. 2024
  Lecturer
  札幌市立川北小学校
• ツール・ド・北海道2016 ドーピングコントロール・シャペロン
  Sep. 2016
  Organizing member

• Jul. 2026
  第50回北海道認定実務実習指導薬剤師養成ワークショップ
  タスクフォース
• Jan. 2025
  第45回北海道認定実務実習指導薬剤師養成ワークショップ
  タスクフォース
• Jul. 2024
  第40回日本TDM学会・学術大会
  ハンズオンセミナー・講師チューター
• Sep. 2023
  令和５年度第一回国公立大学人材育成ワークショップ
  「国公立大学出身の薬剤師博士の多様な活躍の紹介」 発表
• Aug. 2018
  北海道大学薬学部-台北医学大学薬学部 短期交換留学プログラム2018
  平成30年度 第4回スーパージェネラリスト・ファーマシスト養成セミナー
  文部科学省「高度先導的薬剤師の養成とそのグローカルな活躍を推進するアドバンスト教育研究プログラムの共同開発」事業